Study on Human Bioequivalence of Triprerelin Acetate for Injection

PHASE1RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

September 4, 2025

Study Completion Date

September 4, 2025

Conditions
Prostate Cancer (CRPC)
Interventions
DRUG

Triprorelin for injection

Specification: Triprorelin for injection 3.75mg. Produced and supplied by Qilu Pharmaceutical Co.

DRUG

Diphereline

Specification: Diphereline 3.75mg. Produced by Ipsen Pharma Biotech and supplied by Qilu Pharmaceutical Co.

Trial Locations (1)

266003

RECRUITING

The Affiliated Hospital of Qingdao University, Qingdao

All Listed Sponsors
collaborator

Shandong Cancer Hospital and Institute

OTHER

collaborator

Hunan Cancer Hospital

OTHER

collaborator

Shanxi Province Cancer Hospital

OTHER

collaborator

The First Affiliated Hospital of Shanxi Medical University

OTHER

collaborator

The Second Affiliated Hospital of Chongqing Medical University

OTHER

collaborator

First Affiliated Hospital of Chengdu Medical College

OTHER

collaborator

Zibo Central Hospital

OTHER_GOV

collaborator

Yuncheng Central Hospital

OTHER

collaborator

Yichang Central People's Hospital

OTHER

lead

The Affiliated Hospital of Qingdao University

OTHER